OBJECTIVE: The breast lesion excision system (BLES) is a new, automatic percutaneous breast biopsy device that excises single large specimens using radiofrequency cutting. The aim of this study was to determine whether BLES, under stereotactic guidance, can be used as a therapeutic tool in the assessment of small areas of microcalcifications in the breast by providing samples with clear margins. MATERIAL AND METHODS: In this retrospective study, 149 patients with suspicious (BIRADS 4 or 5) small areas of microcalcifications underwent stereotactic-guided BLES. Of these, 34 patients (22.8%) with microcalcifications that had a diameter smaller than the basket size (≤15mm) underwent both BLES and subsequent surgery. Histopathology findings from BLES and subsequent surgery were compared. Identical, underestimation and total excision findings were assessed. RESULTS: BLES revealed fourteen (41.1%) high-risk lesions, ten (29.4%) ductal carcinomas in situ, and ten (29.4%) invasive cancers. Identical results between BLES and surgery were seen in 17/34 (50%) lesions. Surgery confirmed total excision of BLES in 15/34 (44.1%) lesions. Underestimation was seen in 2/34 (5.8%) lesions. CONCLUSION: BLES allows accurate diagnosis of small areas of microcalcifications, with few underestimates. BLES is a diagnostic, but cannot be considered to be a therapeutic tool in the case of suspicious microcalcifications because total excision was seen in only 44.1% of these lesions. Studies are needed to address the therapeutic benefit of this procedure in solid lesions.
OBJECTIVE: The breast lesion excision system (BLES) is a new, automatic percutaneous breast biopsy device that excises single large specimens using radiofrequency cutting. The aim of this study was to determine whether BLES, under stereotactic guidance, can be used as a therapeutic tool in the assessment of small areas of microcalcifications in the breast by providing samples with clear margins. MATERIAL AND METHODS: In this retrospective study, 149 patients with suspicious (BIRADS 4 or 5) small areas of microcalcifications underwent stereotactic-guided BLES. Of these, 34 patients (22.8%) with microcalcifications that had a diameter smaller than the basket size (≤15mm) underwent both BLES and subsequent surgery. Histopathology findings from BLES and subsequent surgery were compared. Identical, underestimation and total excision findings were assessed. RESULTS: BLES revealed fourteen (41.1%) high-risk lesions, ten (29.4%) ductal carcinomas in situ, and ten (29.4%) invasive cancers. Identical results between BLES and surgery were seen in 17/34 (50%) lesions. Surgery confirmed total excision of BLES in 15/34 (44.1%) lesions. Underestimation was seen in 2/34 (5.8%) lesions. CONCLUSION: BLES allows accurate diagnosis of small areas of microcalcifications, with few underestimates. BLES is a diagnostic, but cannot be considered to be a therapeutic tool in the case of suspicious microcalcifications because total excision was seen in only 44.1% of these lesions. Studies are needed to address the therapeutic benefit of this procedure in solid lesions.
Authors: Ulrich Bick; Rubina M Trimboli; Alexandra Athanasiou; Corinne Balleyguier; Pascal A T Baltzer; Maria Bernathova; Krisztina Borbély; Boris Brkljacic; Luca A Carbonaro; Paola Clauser; Enrico Cassano; Catherine Colin; Gul Esen; Andrew Evans; Eva M Fallenberg; Michael H Fuchsjaeger; Fiona J Gilbert; Thomas H Helbich; Sylvia H Heywang-Köbrunner; Michel Herranz; Karen Kinkel; Fleur Kilburn-Toppin; Christiane K Kuhl; Mihai Lesaru; Marc B I Lobbes; Ritse M Mann; Laura Martincich; Pietro Panizza; Federica Pediconi; Ruud M Pijnappel; Katja Pinker; Simone Schiaffino; Tamar Sella; Isabelle Thomassin-Naggara; Anne Tardivon; Chantal Van Ongeval; Matthew G Wallis; Sophia Zackrisson; Gabor Forrai; Julia Camps Herrero; Francesco Sardanelli Journal: Insights Imaging Date: 2020-02-05
Authors: W B G Sanderink; L J A Strobbe; P Bult; M S Schlooz-Vries; S Lardenoije; D J Venderink; I Sechopoulos; N Karssemeijer; W Vreuls; R M Mann Journal: Breast Cancer Res Treat Date: 2020-08-01 Impact factor: 4.872